Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery

2001 ◽  
Author(s):  
S Sivaprasad ◽  
Sorge van ◽  
A
2021 ◽  
Vol 14 (6) ◽  
pp. e240562
Author(s):  
Matthew Gillam ◽  
Theresa Richardson

Postoperative cystoid macular oedema (CMO) is a recognised complication of cataract surgery, occurring in around 1.5% of cases. It is generally managed with topical steroids or non-steroidal anti-inflammatory medications. We present a case of a patient who developed bilateral sequential CMO following bilateral sequential cataract surgery which was non-responsive to topical therapy and worsened following sub-Tenons administration of steroid. The patient took fingolimod for multiple sclerosis both prior to and during the period of cataract surgery which is known to result in the development of macular oedema in some patients. On fingolimod cessation, the oedema resolved over a period of 5 months with good visual recovery. We present this case to inform cataract surgeons of the risk of fingolimod-associated macular oedema in patients undergoing cataract surgery and to inform neurologists of the potential need to adjust treatment for patients undergoing cataract surgery.


Author(s):  
Harish R. Trivedi ◽  
Harsha Maheshwari

Background: Cataract surgery can result in postoperative inflammation which increases the risk of complications like increased intraocular pressure (IOP), uveitis and cystoid macular oedema. We aim to evaluate the effectiveness of topical non-steroidal anti-inflammatory drug bromfenac and topical prednisolone in controlling intraocular inflammation after uncomplicated cataract surgery and compare intraocular pressure (IOP) differences, degrees of anterior chamber inflammation and macular oedema between two different treatments.Methods: 100 patients undergoing manual small incision cataract surgery with PMMA posterior chamber intraocular lens implantation were randomly assigned to receive either Bromfenac (0.09%) eye drops or prednisolone acetate (1%) eye suspension as their postoperative anti-inflammatory medication with 50 cases in each group. The patients were examined at the day 1, day 7, day 15, and day 30 after surgery. Postoperative inflammation was evaluated subjectively by intraocular pressure, slit-lamp assessment of signs of inflammation in the form of aqueous cells and flare and optical coherence tomography to rule out post-operative macular oedema.Results: Both the drugs are equally effective in controlling post-operative inflammation and post-operative cystoid macular oedema.Conclusions: Bromfenac (0.09%) is an effective drug in controlling ocular inflammation after un-complicated cataract surgery having effect similar to topical Prednisolone acetate (1%) with minimal side effects and less frequent dosing.


Author(s):  
Soumendra Sahoo ◽  
Ankur Barua ◽  
Kay Thi Myint ◽  
Adnaan Haq ◽  
Adinegara BL Abas ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document